Introduction

The shift from a one-size-fits-all model to personalized therapies represents one of the most significant advances in modern medicine. Central to this transformation is the ability to culture patient-derived cells—cells taken directly from an individual’s tissue, tumor, or blood—and maintain them in a laboratory setting. These cells serve as living avatars of the patient’s disease, offering unprecedented opportunities to study pathophysiology, predict drug responses, and tailor treatments with high precision. However, successfully culturing patient-derived cells is not trivial; it requires careful optimization of conditions to preserve the cells’ native characteristics, ensure viability, and support functional assays. This article outlines robust strategies for culturing patient-derived cells, from sourcing and processing to advanced culture systems, quality control, and applications in personalized medicine.

Patient-derived cells include a wide range of cell types: cancer cells from biopsies, circulating tumor cells, induced pluripotent stem cells (iPSCs), mesenchymal stem cells, and immune cells such as T cells or natural killer cells. Each type presents unique challenges and demands tailored culture protocols. The overarching goal is to recapitulate the in vivo cellular environment as closely as possible, thereby enabling reliable experimental outcomes that can guide clinical decisions. As personalized therapies become more mainstream, mastering these culture strategies is essential for researchers, clinicians, and biomanufacturers alike.

Sourcing and Processing of Patient-Derived Cells

Tissue Acquisition and Handling

The journey of patient-derived cells begins with the procurement of biological material. Tissues are typically obtained through surgical resections, core needle biopsies, or blood draws. The quality and cellular composition of the starting material heavily influence culture success. Strict coordination between surgical teams, pathologists, and laboratory personnel is necessary to minimize ischemic time and preserve cell viability. Samples should be placed immediately into a transport medium—often a sterile saline solution supplemented with antibiotics and antifungal agents—and kept on ice or at 4 °C until processing. For fragile cells such as tumor-infiltrating lymphocytes, rapid transport in specialized media containing serum or growth factors may be required.

Ethical considerations also play a role; all tissue collection must follow institutional review board protocols and informed consent guidelines. Proper labeling, de-identification, and tracking via barcodes or databases ensure traceability and compliance with regulations. Once in the lab, the tissue is inspected, weighed, and photographed if necessary before proceeding to dissociation.

Cell Dissociation and Purification

To obtain single-cell suspensions suitable for culture, solid tissues must be dissociated. Mechanical mincing with scalpels or scissors is followed by enzymatic digestion. Common enzymes include collagenase, dispase, trypsin, or a combination, depending on the tissue type. For instance, collagenase type IV is widely used for tumor tissues because it digests extracellular matrix while preserving epithelial and stromal cells. Incubation times and enzyme concentrations must be optimized to avoid over-digestion that could damage cell surface receptors or reduce viability. Gentle agitation or rotation during digestion improves contact.

After digestion, the cell suspension is filtered through mesh strainers (e.g., 100 µm or 70 µm) to remove aggregates, and then washed. Red blood cells can be lysed with ammonium‑chloride‑potassium buffer if needed. For further purification, methods such as density gradient centrifugation, magnetic‑activated cell sorting (MACS), or fluorescence‑activated cell sorting (FACS) allow isolation of specific cell types based on size, granularity, or surface markers. This step is critical for removing unwanted cells like fibroblasts or immune cells that may outgrow the target cell population. For example, in culturing patient‑derived tumor cells, depletion of CD45+ leukocytes often improves tumor cell enrichment.

Foundational Culture Strategies

Optimization of Culture Media and Supplements

The choice of culture medium is arguably the most important factor for patient-derived cell growth. Basal media such as DMEM, RPMI‑1640, or advanced DMEM/F12 are commonly used, but they must be supplemented appropriately. Serum (fetal bovine serum, often at 5–20%) provides growth factors, hormones, and attachment factors, but batch‑to‑batch variability can affect reproducibility. For applications requiring defined conditions, serum‑free or xeno‑free media supplemented with recombinant proteins (e.g., EGF, FGF‑2, insulin, transferrin) and specific nutrients are preferred. For stem cell cultures, defined media such as mTeSR™1 or Essential 8™ are essential to maintain pluripotency.

For patient‑derived cancer cells, supplementation with hydrocortisone, cholera toxin (to stimulate cAMP), and defined lipids can enhance proliferation and maintain epithelial morphology. Additionally, antibiotics (penicillin‑streptomycin) and antimycotics (amphotericin B) are standardly added initially to prevent microbial contamination, though long‑term use is discouraged due to potential cellular stress or selection. The pH of the medium should be closely monitored; most mammalian cells thrive at pH 7.2–7.4, maintained by a bicarbonate‑CO₂ buffering system in a 5–10% CO₂ incubator.

Maintenance of Physicochemical Parameters

Beyond medium composition, physical culture conditions greatly influence cell health. Consistent temperature (37 °C), humidity (>95%), and O₂ levels are critical. Many patient‑derived cells, especially those from hypoxic tumor environments, benefit from low oxygen tensions (2–5% O₂) rather than atmospheric 20% O₂. This requires a tri‑gas incubator capable of controlling both CO₂ and O₂. Additionally, the culture substrate matters: standard tissue culture plastic may be adequate for adherent cells, but many patient‑derived cells require coating with extracellular matrix proteins such as collagen, fibronectin, laminin, or Matrigel® to promote attachment and maintain differentiation. For example, mammary epithelial cells cultured on collagen‑coated dishes display more normal morphogenesis.

2D vs. 3D Culture Systems

Traditional two‑dimensional (2D) monolayer cultures on flat plastic have been the workhorse of cell biology for decades, but they often fail to replicate the complex architecture and cell‑cell interactions found in tissues. For patient‑derived cells, three‑dimensional (3D) culture systems have emerged as superior alternatives, providing more physiologically relevant microenvironments. The choice between 2D and 3D depends on the specific research question and the cell type. For rapid drug screening and high‑throughput assays, 2D cultures may suffice, but for studying invasion, angiogenesis, or drug resistance, 3D models are indispensable.

Spheroids and Organoids

Spheroids are simple 3D aggregates formed by culturing cells under non‑adherent conditions, often in ultra‑low attachment plates or hanging drops. They are particularly useful for studying tumor growth, hypoxia gradients, and drug penetration. Organoids, on the other hand, are more complex self‑organizing structures derived from stem or progenitor cells that recapitulate key features of the original tissue, including cellular diversity and tissue‑specific architecture. Patient‑derived organoids (PDOs) have been successfully established for many cancers (e.g., colorectal, pancreatic, prostate, breast) and are now a cornerstone of personalized oncology. Organoid culture requires a specialized medium rich in growth factors (R‑spondin, Noggin, Wnt‑3A) and an extracellular matrix support such as Matrigel®. Protocols for PDOs are available from sources such as Nature Protocols and continue to evolve.

Scaffolds and Biomaterials

For cells that require more structural support, scaffolding approaches using natural or synthetic biomaterials allow precise control over the microenvironment. Decellularized extracellular matrix (dECM) derived from native tissues provides biochemical cues, while synthetic hydrogels based on polyethylene glycol (PEG), alginate, or hyaluronic acid offer tunable stiffness, porosity, and degradation rates. These systems are especially valuable for studying cell‑matrix interactions and for engineering tissues for regenerative medicine. Bioprinting technologies now enable the construction of multi‑cellular 3D constructs with defined spatial organization, opening avenues for more predictive disease models.

Ensuring Quality and Genetic Stability

Genetic Drift and Passaging Limitations

Patient‑derived cells are not immortal; unlike standard cell lines, they have a finite lifespan in culture and are prone to genetic drift if passaged too many times. Repeated subculture can select for minor subpopulations that grow faster, leading to loss of the original phenotype and genomic alterations. Therefore, it is critical to limit passage numbers—typically to under 10 passages for primary cells—and to use early‑passage material for key experiments. For long‑term studies, cryopreservation at early passages is recommended, with banks of vials stored in liquid nitrogen. For stem cells, careful monitoring of karyotype and pluripotency markers is essential, as even iPSCs can acquire chromosomal aberrations over time.

Quality Control Assays

Routine quality control (QC) ensures that patient‑derived cells remain representative of the donor. Basic QC includes morphology checks, viability assessment (trypan blue exclusion, automated counters), and mycoplasma testing by PCR or enzymatic detection. For genetic validation, short tandem repeat (STR) profiling can authenticate the cell line and confirm donor identity. Karyotyping or array comparative genomic hybridization (aCGH) can detect large‑scale chromosomal changes. For functional QC, assays for differentiation potential (for stem cells) or tumorigenicity (for cancer cells) may be necessary. Many laboratories adopt guidelines from organizations like the ATCC to implement robust genetic stability protocols.

Functional Assessment and Applications

Drug Sensitivity Testing

One of the most direct applications of patient‑derived cell cultures is ex vivo drug sensitivity testing. By exposing cultured cells—often in 3D organoid format—to a panel of clinically relevant drugs, researchers can determine which agents are most effective for that individual patient. These assays can be performed in 384‑well plates using viability readouts (e.g., CellTiter‑Glo, ATP detection) or high‑content imaging. Results often correlate with clinical outcomes, enabling oncologists to prioritize treatment options, especially when multiple therapies exist. The National Cancer Institute highlights the role of such approach in precision oncology.

Personalized Treatment Planning

Beyond drug screening, patient‑derived cultures can inform treatment decisions in real time. For example, organoids from rectal cancer biopsies have been used to predict response to chemoradiotherapy, guiding decisions on surgery versus watch‑and‑wait strategies. In immunotherapy, patient‑derived tumor‑infiltrating lymphocytes (TILs) can be expanded ex vivo and re‑infused, while tumor organoids can be used to test immune checkpoint blockers in co‑culture with autologous T cells. The ability to integrate genomic data with functional results from cultured cells further enhances precision—mutations identified by next‑generation sequencing can be correlated with drug sensitivities observed in the lab.

Disease Modeling and Biomarker Discovery

Patient‑derived cells also serve as powerful tools for understanding disease mechanisms. By comparing cultures from patients with different genetic backgrounds or disease stages, researchers can identify biomarkers of progression or resistance. For instance, iPSC‑derived neurons from patients with amyotrophic lateral sclerosis (ALS) recapitulate key pathological features and have been used to test new therapeutics. Similarly, patient‑derived organoids from cystic fibrosis airway cells have enabled functional assays of CFTR modulators, leading to personalized treatment for individuals with rare mutations. These models reduce reliance on animal testing and provide human‑relevant data that can accelerate drug development.

Challenges in Clinical Translation

Contamination and Mycoplasma

Despite best efforts, contamination remains a frequent obstacle. Bacterial, yeast, and fungal infections can devastate cultures, originating from tissue samples or lab reagents. Mycoplasma, in particular, is insidious—it does not cause visible turbidity but alters cell behavior, metabolism, and gene expression. Regular testing (monthly) and strict aseptic technique are non‑negotiable. Use of antibiotics in long‑term culture is discouraged, as it can mask low‑level infections and promote resistance; instead, contaminations should be addressed with specific treatments if possible, or the culture discarded and replaced from frozen stocks.

Cellular Heterogeneity and Selection

Patient tissues are inherently heterogeneous, containing multiple cell types—tumor cells, immune cells, stromal fibroblasts, endothelial cells, and others. Culture conditions often favor a subset, leading to loss of cellular diversity. For example, standard cancer cell cultures may be overtaken by rapidly proliferating fibroblasts if epithelial‑specific conditions are not applied. Techniques such as FACS sorting for surface markers or selective media (e.g., low calcium for keratinocytes) can mitigate this, but some heterogeneity is desirable because it reflects the original tumor microenvironment. Balancing enrichment with preservation of diversity is a challenge that requires careful design of culture protocols.

Scalability and Cost

For widespread clinical use, patient‑derived cell cultures must be scalable, reproducible, and cost‑effective. Producing sufficient cells for high‑throughput drug screens or for therapeutic infusion (e.g., CAR‑T cells) demands large culture volumes and automated platforms. Many current protocols rely on expensive media components (e.g., recombinant growth factors, Matrigel) that are not amenable to large‑scale production. Efforts to develop lower‑cost defined media and synthetic scaffolds are ongoing. Moreover, variability between donors and within the same culture over time complicates standardization. The field is moving toward more robust protocols and quality control measures, as emphasized in reviews on challenges in cell therapy manufacturing.

Future Directions

Automation and High‑Throughput Systems

Robotic liquid handlers, automated incubators, and high‑content imaging systems are increasingly being integrated into workflows for patient‑derived cell culture. These systems reduce hands‑on time, improve reproducibility, and allow parallel processing of many samples. For example, automated organoid culture platforms can seed, feed, and image thousands of organoids in multi‑well plates, enabling systematic drug screening across patient cohorts. Such automation is critical for translating personalized therapies from research to clinical practice where time and consistency matter.

Microfluidic Platforms and Co‑Cultures

Microfluidics offers precise control over the cellular microenvironment at the microscale, enabling perfusion, gradient generation, and spatial compartmentalization. These devices can co‑culture patient‑derived tumor cells with immune cells, endothelial cells, or microbial components to model complex interactions such as tumor‑immune dynamics or drug penetration. Organ‑on‑a‑chip systems further recapitulate multi‑organ crosstalk, and when seeded with patient‑derived cells, they hold promise for personalized pharmacokinetic and pharmacodynamic studies.

Integration with Genomics and AI

The next frontier is the synergy between patient‑derived cell cultures, genomic profiling, and artificial intelligence (AI). Large datasets from drug screens can be used to train machine‑learning models that predict drug responses from genomic features, potentially reducing the need for functional testing in every case. Conversely, images of organoid morphology can be analyzed by deep learning algorithms to classify drug sensitivity or genetic subtypes. As biobanks of patient‑derived cultures grow, they become invaluable resources for training these models, driving a virtuous cycle between experimentation and computational prediction.

Conclusion

Culturing patient‑derived cells is a foundational technology for personalized therapies, enabling clinicians and researchers to capture the unique biology of an individual’s disease. By optimizing sourcing, media composition, and 3D culture systems, and by enforcing rigorous quality control, it is possible to maintain cells that faithfully represent the patient’s condition. Challenges such as contamination, heterogeneity, and scalability remain, but emerging tools in automation, microfluidics, and artificial intelligence promise to overcome these hurdles. As these strategies mature, patient‑derived cell cultures will become even more integral to the development of effective, customized treatments across oncology, regenerative medicine, and beyond. The ultimate goal—delivering the right therapy to the right patient at the right time—depends on our ability to culture these cells reliably and use them to guide clinical decisions.